VacZine Analytics  
MarketVIEW - H1N1 vaccine (US demand model)

Updated: July 2009

Pandemic influenza: Vaccine manufacturers are now actively producing H1N1 pandemic specific vaccine. The WHO SAGE committee has advised that vaccination strategy should focus on protecting the integrity of national healthcare systems and so has prioritized healthcare workers. Prioritization will be especially relevant if initial supplies are limited.

Using currently available information regarding the expected profile, possible allocation of H1N1 specific vaccine and predictions of pandemic severity, VacZine Analytics has modelled a potential vaccine demand scenario in the United States.

The provided model and presentation also give indications of potential cumulative revenue (for vaccine manufacturers) and required antigen amounts (approximation) for a full vaccination campaign.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PRICE*: PURCHASE:
VAMV006 Click here>> USD $1995.00 GBP 1330.00
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20.0%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2011 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains